Researchers at Galenea Corp. will share a five-year, $3 million grant from the National Institute of Mental Health (NIMH) with Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School to develop new biomarkers to measure the effectiveness of drugs aimed at schizophrenia.

Advertisement